ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Small-Cell Lung Cancer in Durham, NC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Lung Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Colorectal Cancer
Triple Negative Breast Cancer

Non-Small-Cell Lung Cancer trials near Durham, NC, USA:

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non...

Enrolling
Metastatic Non Small Cell Lung Cancer
Biological: LN-145

Phase 2

Iovance Biotherapeutics

Chapel Hill, North Carolina, United States and 43 other locations

PDCT in participants with previously untreated Stage IV or recurrent non-small cell lung cancer (NSCLC)....

Active, not recruiting
Metastatic Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
Drug: Nab-Paclitaxel
Drug: Cisplatin

Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Durham, North Carolina, United States and 126 other locations

This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study assessing the activity of durvalumab and chemothe...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: Paclitaxel
Procedure: Surgery

Phase 3

AstraZeneca
AstraZeneca

Durham, North Carolina, United States and 230 other locations

This is an open-label, multicenter, non-randomized, Phase 2 study to determine the safety, tolerability and efficacy of encorafenib given in-...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: encorafenib
Drug: binimetinib

Phase 2

Pfizer
Pfizer

Durham, North Carolina, United States and 156 other locations

with NKTR-255 and anti-PD1 therapy for subjects with refractory non-small cell lung cancer.The purpose o...

Enrolling
Metastatic Non Small Cell Lung Cancer
Biological: C-TIL051

Phase 1

AbelZeta

Raleigh, North Carolina, United States

phase 2 dose (RP2D) of REGN5093 in patients with MET-altered Non-small cell lung cancer (NSCLC).The prim...

Active, not recruiting
NSCLC
Drug: REGN5093

Phase 1, Phase 2

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Durham, North Carolina, United States and 29 other locations

This is a Phase III, randomised, double-blind, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) in combina...

Enrolling
Non-Small Cell Lung Cancer
Drug: Oleclumab
Other: Placebo

Phase 3

AstraZeneca
AstraZeneca

Greensboro, North Carolina, United States and 232 other locations

The purpose of eVOLVE-Lung02 is to test the effectiveness (efficacy) and measure the safety of volrustomig in combination with chemotherapy ...

Enrolling
Metastatic Non-small Cell Lung Cancer
Drug: Pembrolizumab
Drug: Pemetrexed

Phase 3

AstraZeneca
AstraZeneca

Henrico, Virginia, United States and 230 other locations

The study is a prospective, randomized controlled phase III trial, to test the efficacy, safety and neurocognitive outcomes of advanced NSCLC patient...

Active, not recruiting
Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
Other: Best Standard of Care
Device: NovoTTF-200M device

Phase 3

NovoCure
NovoCure

Chapel Hill, North Carolina, United States and 127 other locations

phase II dose (RP2D). Subjects with selected solid tumors including non-small cell lung cancer (NSCLC) w...

Enrolling
Metastatic Cancer
Advanced Cancer
Biological: MEM-288 Intratumoral Injection
Biological: Nivolumab

Phase 1

Memgen

Durham, North Carolina, United States and 1 other location

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems